Dual GIP/GLP-1 receptor agonist
Tirzepatide
Brand names: Mounjaro, Zepbound
Last reviewed 2026-08-01
Women included; analysis limitedPregnancy/lactation data limited
Tirzepatide is approved for type 2 diabetes and chronic weight management in adults in the U.S. Women were well represented numerically in the pivotal obesity trial SURMOUNT-1, but sex-specific conclusions are limited. Pregnancy and lactation data are limited and the label advises stopping treatment before and during pregnancy.
Key takeaways
- Approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) in adults in the U.S.
- Women were numerically well represented in pivotal obesity trials, but sex-specific analyses had limitations.
- Pregnancy and lactation data are limited; label counseling is required.
Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.